AUTHOR=Rodríguez-Martín Eulalia , Nieto-Gañán Israel , Hernández-Breijo Borja , Sobrino Cristina , García-Hoz Carlota , Bachiller Javier , Martínez-Feito Ana , Navarro-Compán Victoria , Lapuente-Suanzes Paloma , Bonilla Gema , Pascual-Salcedo Dora , Roy Garbiñe , Jurado Teresa , Nozal Pilar , Vázquez-Díaz Mónica , Balsa Alejandro , Villar Luisa M. , Plasencia-Rodríguez Chamaida 

TITLE=Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis

JOURNAL=Frontiers in Immunology

VOLUME=11

YEAR=2020

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01913

DOI=10.3389/fimmu.2020.01913

ISSN=1664-3224

ABSTRACT=<p><bold>Background:</bold> TNF inhibitors (TNFis) are widely used for the treatment of rheumatoid arthritis (RA), although the response rates to this therapy in patients with RA remains heterogeneous and &lt; 50% achieve remission (REM).</p><p><bold>Objective:</bold> To analyze baseline peripheral blood leukocytes profiles in order to search for biomarkers identifying patients who will most likely not achieve REM under TNFi treatment.</p><p><bold>Methods:</bold> A prospective bi-center pilot study including 98 RA patients treated with TNFis and followed-up during 6 months. Patients were classified according to DAS28 as follows: those who achieved REM (DAS28 ≤ 2.6) and those who did not (DAS28 &gt; 2.6) at 6 months after starting TNFis. These rates were also assessed by simplified disease activity index (SDAI ≤ 3.3 and SDAI &gt; 3.3, respectively). Peripheral blood immune cells were studied by flow cytometry before treatment initiation.</p><p><bold>Results:</bold> At 6 months, 61 or 80% of patients did not achieve REM by DAS28 or SDAI, respectively. Basal leukocyte profiles differed between REM vs. non-REM patients. Non-REM patients showed lower percentages of total and naïve B cells at baseline than REM subjects. A B lymphocyte/CD4+ lymphocyte ratio (BL/CD4 ratio) &lt;0.2 clearly associated with a higher probability of non-REM status based on DAS28 at 6 months (OR = 9.2, <italic>p</italic> = 0.006). These data were confirmed when patient response was evaluated by SDAI index.</p><p><bold>Conclusion:</bold> Our results strongly suggest that BL/CD4 ratio could be considered as a useful biomarker for the early identification of non-remitters to TNFi in clinical practice.</p>